Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 13/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20917114 | 0.89 | CACNA2D1 (0.46) | CACNA2D1SLC6A2 | |
| SCHEMBL28421874 | 0.88 | CACNA2D1 (0.42) | CACNA2D1SLC6A2 | |
| SCHEMBL20917115 | 0.88 | CACNA2D1 (0.42) | CACNA2D1SLC6A2SLC6A4 | |
| SCHEMBL20917072 | 0.86 | SLC6A4 (0.59) | CACNA2D1SLC6A2SLC6A4 | |
| SCHEMBL30438571 | 0.84 | CACNA2D1 (0.43) | CACNA2D1SLC6A2 | |
| SCHEMBL30438564 | 0.83 | CACNA2D1 (0.56) | CACNA2D1SLC6A2 | |
| SCHEMBL20917125 | 0.83 | CACNA2D1 (0.56) | CACNA2D1SLC6A2 | |
| SCHEMBL30438577 | 0.83 | SLC6A4 (0.51) | CACNA2D1SLC6A2SLC6A4 | |
| SCHEMBL20917311 | 0.83 | SLC6A4 (0.51) | CACNA2D1SLC6A2SLC6A4 | |
| SCHEMBL22714192 | 0.82 | SLC6A4 (0.59) | CACNA2D1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111225901-B | Propylamine derivatives for the treatment of pain and pain-related disorders | 埃斯特韦制药股份公司 | 2023-07-04 | — | — | CN | claimed |
| US-11111220-B2 | Propanamine derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-09-07 | — | — | US | claimed |
| US-20200377464-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-12-03 | — | — | US | claimed |
| EP-3697754-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-08-26 | — | — | EP | claimed |
| CN-111225901-A | Propylamine derivatives useful in the treatment of pain and pain-associated conditions | 埃斯特韦制药股份公司 | 2020-06-02 | — | — | CN | claimed |
| WO-2019076904-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-04-25 | — | — | WO | claimed |
| CN-111225901-B | Propylamine derivatives for the treatment of pain and pain-related disorders | 埃斯特韦制药股份公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11111220-B2 | Propanamine derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-09-07 | — | — | US | disclosed |
| US-11111220-B2 | Propanamine derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-09-07 | — | — | US | disclosed |
| US-20200377464-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-12-03 | — | — | US | disclosed |
| US-20200377464-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-12-03 | — | — | US | disclosed |
| EP-3697754-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-08-26 | — | — | EP | disclosed |
| CN-111225901-A | Propylamine derivatives useful in the treatment of pain and pain-associated conditions | 埃斯特韦制药股份公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019076904-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019076904-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377464-A1 | PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1G, CACNA1B, CACNA1I | CACNA2D1 19/4885SLC6A2 39/4885SLC6A4 173/4885 |
| US-11111220-B2 | Propanamine derivatives for treating pain and pain related conditions | CACNA1G, CACNA1B, CACNA1I | CACNA2D1 19/4885SLC6A2 39/4885SLC6A4 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.